Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAHTMDPT6XyaNv0R67W6y6nJwpAEHJF9fWpEuYXfoUtgo#assertion>. }
Showing items 1 to 13 of
13
with 100 items per page.
- MONDO_0007079 type Disease assertion.
- association type Statement assertion.
- context type Cohort assertion.
- DRUGBANK:DB00657 type Drug assertion.
- association label "The nicotinic-acetylcholine receptor (nAchR)- antagonist mecamylanine has been found to reduce the stimulus produced by ethanol in human lab studies. The nAchR-antagonist varenicline has also displayed positive effect in reducing alcohol consumption in multiple clinical trials. In this 12- week double-blind trial, participants (n 1⁄4 126) were randomized to either mecamylamine (10 mg daily) or placebo. No medication effect was found for reducing heavy drinking days (HDD) or alcohol craving. Smoking status had no effect on the results. The authors suggest that broad-spectrum nAchR-antagonists may not be beneficial in treat- ing AUD" assertion.
- context label "Adults" assertion.
- association object MONDO_0007079 assertion.
- association predicate treats assertion.
- association subject DRUGBANK:DB00657 assertion.
- association relation OffLabelIndication assertion.
- association publications 30973369 assertion.
- association provided_by NeuroDKG assertion.
- association has_population_context context assertion.